Herceptin, Trastuzumab Newswire (Page 8)

Herceptin, Trastuzumab Newswire (Page 8)

Comprehensive Real-Time News Feed for Herceptin, Trastuzumab (generic). (Page 8)

Results 141 - 160 of 1,076 in Herceptin, Trastuzumab (generic)

  1. Study Finds Significant Cost Differences Among Breast Cancer Chemotherapy RegimensRead the original story

    Oct 10, 2016 | P&T Community

    Costs associated with different breast cancer chemotherapy regimens can vary significantly regardless of effectiveness, according to new research from the University of Texas MD Anderson Cancer Center. Understanding cost differences can help guide informed discussions between patients and physicians when considering chemotherapy options.

    Comment?

  2. Daiichi Sankyo Presents Late-Breaking Phase 1 Data For Novel...Read the original story

    Oct 9, 2016 | BioSpace

    These results, from the dose escalation part of a two-part phase 1 study of DS-8201a, will be presented today during a late-breaking poster discussion session at the ESMO 2016 Congress, the annual meeting of the European Society for Medical Oncology . DS-8201a is an investigational antibody drug conjugate comprised of a humanized anti-HER2 antibody attached by a peptide linker to a novel topoisomerase I inhibitor payload, utilizing Daiichi Sankyo's proprietary payload and linker-payload technology.

    Comment?

  3. Cascadian Therapeutics Announces Presentation Of Tucatinib In...Read the original story

    Oct 9, 2016 | BioSpace

    Cascadian Therapeutics , a clinical-stage biopharmaceutical company, today announced the presentation of clinical activity of tucatinib, its investigational, highly selective small molecule HER2 inhibitor, in combination therapy at the European Society for Medical Oncology 2016 Congress being held October 7-11, 2016 in Copenhagen, Denmark. Data from the poster presentation , an Oral HER2-Specific Inhibitor in Combination with Capecitabine and/or Trastuzumab in Third Line or Later Treatment"), reported on responses of skin lesions in HER2+ metastatic breast cancer patients following treatment with tucatinib in combination with capecitabine and/or trastuzumab.

    Comment?

  4. Study finds significant cost differences between breast cancer chemotherapy regimensRead the original story w/Photo

    Oct 10, 2016 | PhysOrg Weblog

    Micrograph showing a lymph node invaded by ductal breast carcinoma, with extension of the tumour beyond the lymph node. Credit: Nephron/Wikipedia Costs associated with different breast cancer chemotherapy regimens can vary significantly, regardless of effectiveness, according to new research from The University of Texas MD Anderson Cancer Center.

    Comment?

  5. Breast cancer: Similarly effective treatments vary in costRead the original story w/Photo

    Oct 10, 2016 | Medical News Today

    The cost of chemotherapy treatment for breast cancer can vary widely, and higher cost does not necessarily mean greater effectiveness. These are the findings of a new study published online in Cancer and presented at the 2016 American Society of Clinical Oncology Annual Meeting in Chicago, IL.

    Comment?

  6. MD Anderson Study Finds Significant Cost Differences Between Breast Cancer Chemotherapy RegimensRead the original story

    Oct 9, 2016 | Newswise

    Costs associated with different breast cancer chemotherapy regimens can vary significantly, regardless of effectiveness, according to new research from The University of Texas MD Anderson Cancer Center . Understanding cost differences can help guide informed discussions between patients and physicians when considering chemotherapy options.

    Comment?

  7. Costs of similarly effective breast cancer treatments vary widelyRead the original story w/Photo

    Oct 9, 2016 | EurekAlert!

    A new study finds that the costs of breast cancer chemotherapy vary widely, even among treatment regimens with similar efficacy, and that patients bear a substantial out-of-pocket burden. Published early online in CANCER , a peer-reviewed journal of the American Cancer Society, the study is the first to examine these cost differences, providing clinicians with accessible information to answer patient questions about their treatment options.

    Comment?

  8. Deal Watch: Teva and Celltrion Announce Biosimilar Commercial PartnershipRead the original story w/Photo

    Oct 6, 2016 | JD Supra

    Teva Pharmaceutical Industries Ltd., Celltrion, Inc. and Celltrion Healthcare announced that the companies have entered into an exclusive partnership to commercialize two of Celltrion's biosimilar candidates: CT-P10, a proposed mAb biosimilar to Rituxan , and CT-P6, a proposed mAb biosimilar to Herceptin .

    Comment?

  9. Teva, Celltrion Enter Biosimilar PartnershipRead the original story w/Photo

    Oct 6, 2016 | Contract Pharma Breaking News

    Teva Pharmaceutical and Celltrion have entered into an exclusive partnership to commercialize two of Celltrion's mAb biosimilar candidates in the U.S. and Canada. CT-P10 is a proposed mAb biosimilar to Rituxan , which is used to treat Non-Hodgkin's Lymphoma , Chronic Lymphocytic Leukemia , Rheumatoid Arthritis , Wegener's Granulomatosis and Microscopic Polyangiitis .

    Comment?

  10. Researchers identify new strategy to selectively sensitize cancer cells to radiation therapyRead the original story w/Photo

    Oct 5, 2016 | Medical News

    Many types of cancer become drug resistant, making them difficult to treat. Researchers with University of California San Diego School of Medicine and Moores Cancer Center have identified a strategy to selectively sensitize certain cancer cells to radiation therapy that may improve tumor control and reduce treatment-related side effects.

    Comment?

  11. Cascadian Therapeutics Announces Proposal For Reverse Stock SplitRead the original story

    Oct 4, 2016 | BioSpace

    Cascadian Therapeutics , a clinical-stage biopharmaceutical company, today announced that its board of directors has approved a plan for a reverse split of the Company's common stock to increase its share price and reduce the number of authorized and outstanding shares. "The board and management have worked diligently on several facets of the Company this year to position it for the future, including bringing in new management, and solidifying our product development and regulatory strategies.

    Comment?

  12. 5 Of The Biggest Breast Cancer Breakthroughs Of 2016Read the original story w/Photo

    Oct 4, 2016 | Medical Daily

    This October, we take time to raise awareness about breast cancer. While most of the focus tends to be on prevention and working toward an eventual cure, we tend to lose track of how fun we've already come.

    Comment?

  13. Antibody drug conjugates may help personalize radiotherapy for patients with cancerRead the original story w/Photo

    Oct 4, 2016 | PhysOrg Weblog

    UC San Diego School of Medicine and Moores Cancer Center researchers report that in mouse models tumors testing positive for a protein called human epidermal growth factor receptor 2 were sensitized to a combination of radiation therapy and an antibody drug conjugate , called ado-trastuzumab emtansine pictured here in red binding to tumor cells. Credit: UC San Diego Health Many types of cancer become drug resistant, making them difficult to treat.

    Comment?

  14. Samsung Bioepis' Marketing Authorization Application For SB3...Read the original story

    Oct 3, 2016 | BioSpace

    Samsung Bioepis Co., Ltd. today announced that the European Medicines Agency has accepted for review the company's Marketing Authorization Application for SB3, a biosimilar candidate referencing HerceptinA . HerceptinA is a monoclonal antibody indicated for the treatment of early breast cancer, metastatic breast cancer and metastatic gastric cancer.

    Comment?

  15. Lawsuit for Investors in shares of Puma Biotechnology Inc (NYSE:PBYI) ...Read the original story w/Photo

    Oct 4, 2016 | GlobeNewswire

    The Shareholders Foundation, Inc. announces that a lawsuit was filed by an investor in shares of Puma Biotechnology Inc against certain directors of Puma Biotechnology Inc over alleged breaches of fiduciary duties. Investors who purchased shares of Puma Biotechnology Inc in 2013 or earlier and continue to hold any of those NYSE:PBYI shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1 779 - 1554.

    Comment?

  16. .com | Profit before saving livesRead the original story w/Photo

    May 4, 2016 | News24

    According to a recent study, in South Africa nearly 45% of people seeking treatment for prescription medicine dependence reported the use of opiate painkillers. Dr. Delgado tells us more about "mechanistic" vs "vitalistic" approaches to healthcare.

    Comment?

  17. BRIEF-Jiangsu Bicon Pharma plans new material project with investment of 1.5 bln yuanRead the original story w/Photo

    Sep 29, 2016 | Reuters

    BEIJING, Sept 29 In the shadow of one of China's top cancer hospitals in Beijing, a catacomb-like network of ramshackle brick buildings has become a home-from-home for hundreds of cancer patients and their families waiting for treatment.

    Comment?

  18. Galena Biopharma to Present NeuVax (nelipepimut-S) Interim Safety...Read the original story w/Photo

    Sep 29, 2016 | GlobeNewswire

    Galena Biopharma to Present NeuVaxa Interim Safety Data at the European Society for Medical Oncology 2016 Congress SAN RAMON, Calif., Sept. 29, 2016 -- Galena Biopharma, Inc. , a biopharmaceutical company committed to the development and commercialization of hematology and oncology therapeutics that address unmet medical needs, today announced that interim safety data from the Company's NeuVaxa Phase 2b combination study will be presented at the upcoming European Society for Medical Oncology 2016 Congress in Copenhagen, Denmark.

    Comment?

  19. Cascadian Therapeutics Announces Poster Presentations On Tucatinib At The CongressRead the original story

    Sep 27, 2016 | BioSpace

    Cascadian Therapeutics , a clinical-stage biopharmaceutical company, today announced two upcoming poster presentations on tucatinib , the Company's lead product candidate for the treatment of HER2+ breast cancer, at the European Society of Medical Oncology 2016 Congress being held October 7 -11, 2016 in Copenhagen, Denmark.

    Comment?

  20. Daiichi Sankyo To Present At Late-Breaking Clinical Data For Novel...Read the original story

    Sep 26, 2016 | BioSpace

    "Additionally, for the first time we will be showcasing our innovative in-house antibody drug conjugate technology that was used to develop DS-8201a." LBA17: Single Agent Activity of DS-8201a, a HER2-Targeting Antibody-Drug Conjugate, in Breast Cancer Patients Previously Treated with T-DM1: Phase 1 Dose Escalation .

    Comment?